Recorded on 07/12/23
TD Cowen analyst Yaron Werber speaks with John Murphy, Chief Policy Officer & Healthcare Counsel at the Biotechnology Innovation Organization (BIO) about how the Inflation Reduction Act (IRA) will impact innovation in biotech. We discuss how key drug pricing reform provisions of the IRA (e.g., orphan drug exclusion, calculation of maximum fair price, small molecule vs biologics) might impact incentive structures in drug development, the likelihood of revisions to the bill near term, its potential effects on formulary/benefit design, and the first wave of IRA litigation.
For Disclosures, click here bit.ly/3cPHkNW
https://go.td.com/PodcastDisclosure
